2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Radiation Injuries
4
Medulloblastoma
3
Choroid Plexus Neoplasms
3
Central Nervous System Neoplasms
3
Brain Neoplasms
3
Astrocytoma
3
Pinealoma
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive
2
Meningioma
2
Gliosarcoma
2
Glioma, Subependymal
2
Glioma
2
Glioblastoma
2
Fatigue
2
Ependymoma
2
Depression
2
Craniopharyngioma
2
Cognitive Dysfunction
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Retention
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Sleep Wake Disorders
1
Pain
1
Optic Nerve Glioma
1
Neurotoxicity Syndromes
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
Morphine
7
Surveys and Questionnaires
6
Ketamine
5
Fentanyl
4
Sodium Chloride
3
Saline Solution
3
Lidocaine
3
Educational Status
3
Dexmedetomidine
3
Cognitive Behavioral Therapy
3
Anesthetics, Local
3
ziconotide
2
Pregabalin
2
Mindfulness-Based Stress Reduction
2
Hypnosis
2
Control Groups
2
Bupivacaine
2
Botulinum Toxins, Type A
2
Acetaminophen
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
tianeptine
1
siltuximab
1
onabotulinum toxin A
1
nabiximols
1
morphine, naltrexone combination
1
erenumab
1
Yoga
1
Waiting Lists
1
Transcutaneous Electric Nerve Stimulation
1
Tramadol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Chronic Pain
×
Donepezil
×
Clear all
NCT05254639
2024-04-05
DONEPEZOX
University Hospital, Clermont-Ferrand
Phase 2
Completed
77 enrolled